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2151development of CVD. No statistically signiﬁcant in-
teractions by sex or race were found on the relation-
ship between VAT or LBAT and CVD in fully adjusted
models.
Here we report substantial heterogeneity in the
cardiovascular phenotype of obesity, with increased
risk observed with VAT and decreased risk with LBAT.
In contrast, BMI, abdominal SAT, and liver fat were
not signiﬁcantly associated with CVD. Our ﬁndings
suggest that the biological link between fat distribu-
tion and CVD may be at least partly independent of
traditional CVD risk factors and the inﬂuence of
inﬂammation and adipocytokines but that diabetes
may have a role in the etiological pathway between
VAT and CVD. Findings with lean mass and physical
activity are consistent with data that increasing
muscle mass and physical activity may counteract the
negative effects of VAT through fatty acid catabolism
and prevention of insulin resistance (3). The mecha-
nism behind the protective effect of LBAT may relate
to its ability to act as a metabolic sink, buffering the
inﬂux of dietary lipids and protecting other tissues,
including the heart, from lipotoxicity caused by lipid
overﬂow and ectopic fat deposition (4).
Although we focus primarily on the divergent
biology of different adipose depots in the devel-
opment of CVD, our ﬁndings also suggest that ad-
vanced imaging tools may provide a more accurate
phenotypic characterization of obesity than standard
anthropometric measurements, allowing better dis-
crimination of CVD risk. They also suggest that
therapies aimed at redistribution of fat away from
the visceral depot toward the more favorable lower
body subcutaneous depot may be more effective for
preventing cardiovascular complications in obesity
than simply targeting body mass reduction. Whether
modiﬁed diet, exercise, pharmacologic agents, or
bariatric surgery can promote this favorable redistri-
bution of body fat has yet to be determined. Larger
studies are needed to determine if adipose depot–
speciﬁc measurement can improve risk assessment
or serve as a treatment target in obese patients.*Ian J. Neeland, MD
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Copper, Coronary
Heart Disease, and
DehydroepiandrosteroneTivesten et al. (1) measured dehydroepiandrosterone
(DHEA) in serum of nearly 2,500 Swedish men aged
69 to 81 years. Low serum levels of DHEA and its
sulfate predicted increased risk of coronary heart
disease death after 5 years. They reviewed more than
a dozen earlier articles, mentioned that some people
use DHEA as a dietary supplement, and made a plea
for mechanistic studies.
Adult rats have concentrations of DHEA similar to
those in their Table 2. These can be halved by copper
deﬁciency because copper enzymes generally are
oxidative and DHEA is synthesized from cholesterol
by oxidation (2).
The Western diet often is low in copper, and cop-
per values in dietary surveys are falsely high (3).
Copper deﬁciency is the only nutritional insult that
elevates cholesterol, blood pressure, homocysteine,
isoprostanes, and uric acid; has adverse effects
on arteries and electrocardiograms; impairs glucose
tolerance and paraoxonase activity; promotes
thrombosis and oxidative damage; and to which
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2152males respond differently than females. More than 80
anatomic, chemical, and physiological similarities
between animals deﬁcient in copper and people with
ischemic heart disease have been identiﬁed (4,5).
Perhaps low DHEA in their subjects (1) was a subtle,
indirect sign of copper deﬁciency. People who believe
that high concentrations of DHEA are beneﬁcial may
ﬁnd that copper supplements are less expensive and
less hazardous than DHEA supplements. A supple-
ment containing copper produced improvement in
heart failure.*Leslie M. Klevay, MD, SD in Hyg
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Recognizing Sex
Similarities in
Cardiovascular
Disease ResearchWe read the interesting article by Tivesten et al. (1),
which concluded that low serum dehydroepiandros-
terone (DHEA) and its sulfate predict an increased
risk of coronary heart disease in men. This study
examined a cohort of 2,416 elderly men, and previ-
ously we evaluated DHEA-S in 270 women. In
our National Heart, Lung, and Blood Institute–
Women’s Ischemia Syndrome Evaluation study (2),
we found among postmenopausal women undergoing
coronary angiography for suspected myocardial
ischemia, that lower circulating DHEA-S predicted
higher cardiovascular disease (CVD) mortality and all-
cause mortality, similar to the Tiversten et al.ﬁndings among men. Furthermore, this relationship
was independent of other major CVD risk factors but
was attenuated for presence or severity of angio-
graphic coronary artery disease. Our ﬁndings sug-
gested that DHEA-S levels and CVD mortality could be
mechanistically linked to atherosclerosis.
A large portion of THE Tivesten et al. (1) discussion
focused on possible mechanisms for DHEA/-S to
reduce risk of cardiovascular events and we believe
that our research ﬁndings are an important addition
to support this discussion. Although Tivesten et al. (1)
cited studies that included women, the discussion
only mentioned men, and did not mention our sex-
speciﬁc study (2). It is important that contemporary
research not perseverate the historical “male-
pattern” biomedical model where studies in women
are either ignored, as was the case in the Tivesten
et al. article, or made to ﬁt into male diagnostic and
therapeutic standards (3,4). It is similarly important
to evaluate and demonstrate areas where women and
men have similar ﬁndings, as the Tivesten et al. and
our prior WISE study demonstrate.*Chrisandra Shufelt, MD, MS
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